A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema

Summary

The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).

Timeline

Start

2020-09-07

Primary completion

2022-04-11

Completion

2022-04-11

Outcome

Outcome not reported

Stopped: “The study was terminated as the study met the prespecified threshold for futility of less than (\<) 20 percentage (%), based on interim analysis (IA).”

Drugs

Indications